Matteo Lambertini, MD PhD· @matteolambe · X·· 1 天前评分45
正文 · 原文
Oral abstract #BreastCancer session at #ESMO26: no overall survival benefit with the #AKT inhibitor #ipatasertib added to #fulvestrant in patients with advanced endocrine-resistant disease
@OncoAlert @myESMO #bcsm
53 浏览 · 3 赞 · 3 转发 · 0 回复
会议摘要
LBA14按 Proffered paper 2: Breast cancer, early and advanced stage 对上
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.org来源：Matteo Lambertini, MD PhD · x.com